96 related articles for article (PubMed ID: 7495960)
1. Virus inactivation procedures: an overview.
Tedder R
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S13-4. PubMed ID: 7495960
[TBL] [Abstract][Full Text] [Related]
2. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
3. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
4. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
[TBL] [Abstract][Full Text] [Related]
5. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006.
Polizzotto MN; Wood EM; Ingham H; Keller AJ;
Transfusion; 2008 Jan; 48(1):55-63. PubMed ID: 17894794
[TBL] [Abstract][Full Text] [Related]
6. Trends in transfusion-transmitted viral infections from 2001 to 2006 in Ibadan, Nigeria.
Fasola FA; Kotila TR; Akinyemi JO
Intervirology; 2008; 51(6):427-31. PubMed ID: 19321928
[TBL] [Abstract][Full Text] [Related]
7. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
8. Strategies for viral inactivation.
Horowitz B; Ben-Hur E
Curr Opin Hematol; 1995 Nov; 2(6):484-92. PubMed ID: 9372040
[TBL] [Abstract][Full Text] [Related]
9. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
[TBL] [Abstract][Full Text] [Related]
10. Beyond HIV, HBV and HCV--how to deal with other viruses?
Minor PD
Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
[TBL] [Abstract][Full Text] [Related]
11. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
Blejer JL; Saguier MC; Salamone HJ; Carreras LA
Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
[TBL] [Abstract][Full Text] [Related]
12. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
13. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Japan.
Yugi H; Hino S; Satake M; Tadodoro K
Vox Sang; 2005 Nov; 89(4):265. PubMed ID: 16262762
[No Abstract] [Full Text] [Related]
14. Progress in improving the pathogen safety of red cell concentrates.
Chapman J
Vox Sang; 2000; 78 Suppl 2():203-4. PubMed ID: 10938953
[TBL] [Abstract][Full Text] [Related]
15. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.
Coste J; Reesink HW; Engelfriet CP; Laperche S; Brown S; Busch MP; Cuijpers HT; Elgin R; Ekermo B; Epstein JS; Flesland O; Heier HE; Henn G; Hernandez JM; Hewlett IK; Hyland C; Keller AJ; Krusius T; Levicnik-Stezina S; Levy G; Lin CK; Margaritis AR; Muylle L; Niederhauser C; Pastila S; Pillonel J; Pineau J; van der Poel CL; Politis C; Roth WK; Sauleda S; Seed CR; Sondag-Thull D; Stramer SL; Strong M; Vamvakas EC; Velati C; Vesga MA; Zanetti A
Vox Sang; 2005 May; 88(4):289-303. PubMed ID: 15877653
[No Abstract] [Full Text] [Related]
16. [Plasma donor screening and product safety].
Storch H; Ponsel G; Igel H; Worofka R
Beitr Infusionsther Transfusionsmed; 1997; 34():31-6. PubMed ID: 9417350
[TBL] [Abstract][Full Text] [Related]
17. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands.
Van der Bij AK; Coutinho RA; Van der Poel CL
Transfusion; 2006 Oct; 46(10):1729-36. PubMed ID: 17002629
[TBL] [Abstract][Full Text] [Related]
19. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
20. West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Nov; 58(45):1263-7. PubMed ID: 19940831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
